Medicare GLP-1 coverage has undergone historic changes thanks to the Inflation Reduction Act (IRA), the Treat and Reduce Obesity Act (TROA) provisions, and CMS's evolving approach to anti-obesity medications. If you are a Medicare beneficiary interested in GLP-1 medications, 2026 looks dramatically different from even two years ago. This guide explains exactly what has changed, what is covered, and how to maximize your benefits.
Quick Answer
Medicare Part D now covers GLP-1 medications for both type 2 diabetes and — for the first time — chronic weight management. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending significantly reduces exposure. The CMS BALANCE model is expanding access to anti-obesity medications for qualifying Medicare beneficiaries. Ozempic, Wegovy, Zepbound, and select other GLP-1s are available, though formulary placement and prior authorization vary by plan.
What the Inflation Reduction Act Changed
The IRA transformed Medicare drug coverage in several critical ways:
$2,000 Annual Out-of-Pocket Cap
Starting January 1, 2025, Medicare Part D beneficiaries pay no more than $2,000 per year in out-of-pocket prescription drug costs. This cap applies across all Part D covered medications, not per drug. For GLP-1 users who previously faced thousands in annual costs during the coverage gap ("donut hole"), this is transformative.
- The cap includes deductible payments, copays, and coinsurance
- Once you hit $2,000, you pay $0 for the rest of the year
- Medicare offers the Medicare Prescription Payment Plan to spread costs across monthly installments
Drug Price Negotiation
The IRA gave CMS the authority to negotiate prices for select high-cost drugs. While specific GLP-1s are subject to the ongoing negotiation timeline, the pricing pressure has already influenced list prices and plan formulary decisions.
Elimination of the Coverage Gap
The IRA effectively eliminated the Part D "donut hole" by replacing the old cost-sharing structure with the hard $2,000 cap. Previously, GLP-1 users could face months of 25% coinsurance on drugs costing $1,000+ per month. That exposure is now capped.
Medicare Weight-Loss GLP-1 Coverage
Historically, Medicare explicitly excluded coverage for drugs used solely for weight loss. This has changed substantially:
TROA and Legislative Expansion
Legislative efforts including the Treat and Reduce Obesity Act provisions have expanded Medicare's ability to cover anti-obesity medications. CMS has been implementing these expansions through:
- Coverage for FDA-approved AOMs when prescribed for chronic weight management in beneficiaries who meet clinical criteria
- CMS BALANCE model — a Medicare demonstration project testing expanded AOM access with structured behavioral counseling
- Medicare Advantage plan flexibility — MA plans can offer supplemental benefits including enhanced AOM coverage
CMS BALANCE Model
The CMS BALANCE (Behavioral counseling And anti-obesity medication for Long-term well-being, A New CMS Effort) model is a key pathway for Medicare GLP-1 access:
- Available in participating Part D plans and Medicare Advantage plans
- Covers FDA-approved AOMs including Wegovy and Zepbound for qualifying beneficiaries
- Requires concurrent participation in behavioral counseling (Intensive Behavioral Therapy for obesity)
- BMI criteria: ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidity
- Not available in all geographic areas or all plans — check with your specific plan
Which GLP-1s Are Covered Under Medicare
| Medication | Indication | Part D Coverage | Medicare Advantage | Notes |
|---|---|---|---|---|
| Ozempic | Type 2 Diabetes | Covered (with PA) | Covered (with PA) | Most widely covered GLP-1 in Medicare |
| Mounjaro | Type 2 Diabetes | Covered (with PA) | Covered (with PA) | Formulary position varies by plan |
| Wegovy | Weight Management | Expanding via BALANCE model | Expanding via supplemental benefits | Requires behavioral counseling component |
| Zepbound | Weight Management | Expanding via BALANCE model | Expanding via supplemental benefits | Some MA plans offering as enhanced benefit |
| Foundayo | Weight/Diabetes | Under formulary review | Select plans adding in 2026 | Oral format attractive for Medicare population |
| Rybelsus | Type 2 Diabetes | Covered (with PA) | Covered (with PA) | Oral semaglutide for diabetes |
Part D vs. Medicare Advantage Coverage
Original Medicare + Part D
- GLP-1 coverage depends on the specific Part D plan you choose
- Each plan has its own formulary, tier structure, and PA criteria
- The $2,000 cap applies regardless of which Part D plan you have
- BALANCE model participation depends on whether your Part D plan is enrolled
Medicare Advantage (Part C)
- MA plans include drug coverage (MAPD) and can offer supplemental benefits
- Some MA plans have added enhanced AOM coverage as a supplemental benefit
- MA plans can offer lower copays for GLP-1s than standalone Part D plans
- Check during Annual Enrollment Period (October 15 – December 7) for plans with GLP-1 coverage
What GLP-1s Cost Under Medicare in 2026
| Phase | What You Pay | Notes |
|---|---|---|
| Deductible phase | $590 deductible (2026) | You pay 100% until deductible is met |
| Initial coverage | 25% coinsurance typical | Plan pays 75%, you pay 25% |
| After $2,000 cap | $0 | You pay nothing for the rest of the year |
Real-World Cost Example
For a Medicare beneficiary taking Wegovy at ~$1,300/month:
- Month 1: $590 deductible → then 25% of remaining = ~$178 → total ~$768
- Month 2: 25% of $1,300 = ~$325 → running total ~$1,093
- Month 3: 25% of $1,300 = ~$325 → running total ~$1,418
- Month 4: Pay ~$582 to hit cap → running total $2,000
- Months 5–12: $0 per month
Under the old Part D structure, this same beneficiary might have paid $3,000–$6,000+ annually. The $2,000 cap is a meaningful improvement.
Medicare Prescription Payment Plan
CMS introduced the Medicare Prescription Payment Plan to help beneficiaries manage costs:
- Spreads your out-of-pocket costs across monthly payments throughout the year
- No interest, no fees
- Available starting in 2025 for all Part D beneficiaries
- Opt in through your Part D plan or at the pharmacy
- Particularly helpful for GLP-1 users who face high costs early in the year
How to Get GLP-1 Coverage on Medicare
- For diabetes: Ask your physician to prescribe the GLP-1 with diabetes ICD-10 codes. Coverage is most straightforward for T2D indications.
- For weight management: Check if your Part D plan or MA plan participates in the BALANCE model or offers AOM supplemental benefits.
- During open enrollment: Compare Part D plans and MA plans specifically for GLP-1 formulary coverage using Medicare Plan Finder at medicare.gov.
- Extra Help / LIS: If you qualify for the Low-Income Subsidy (Extra Help), your copays may be as low as $0–$11 per prescription.
- State Pharmaceutical Assistance Programs: Some states offer additional drug cost assistance that layers on top of Medicare Part D.
Prior Authorization Under Medicare
PA requirements for Medicare GLP-1s follow similar patterns to commercial insurance but with CMS-specific rules:
- Plans must respond to PA requests within 72 hours for standard requests (24 hours for expedited)
- You have the right to a coverage determination review if denied
- Appeals go through a structured process: plan redetermination → Independent Review Entity (IRE) → Administrative Law Judge → Medicare Appeals Council → Federal Court
- The multi-level appeal process takes longer but is thorough, and Medicare beneficiaries win appeals at meaningful rates
Important Limitations
- Manufacturer copay cards are NOT valid for Medicare: Savings programs from Novo Nordisk and Eli Lilly are prohibited for government-insured patients
- Coverage for weight loss is not universal: Not all Part D plans or MA plans cover AOMs, even with recent expansions
- Behavioral counseling requirement: BALANCE model coverage requires concurrent participation in IBT — this is an extra appointment commitment
- Formulary changes: Part D plans can change formularies mid-year (with notice), which could affect your coverage
Bottom Line
Medicare GLP-1 coverage in 2026 is the best it has ever been. The $2,000 out-of-pocket cap transformed the economics. Weight-loss GLP-1 coverage is expanding through the BALANCE model and MA supplemental benefits. Diabetes GLP-1 coverage is well-established. The Prescription Payment Plan helps manage timing. But coverage is still plan-specific, and choosing the right Part D or MA plan during enrollment is critical.
Use MedSwitcher's Medicare comparison tools to find Part D and Medicare Advantage plans that cover your GLP-1 medication at the lowest out-of-pocket cost.
Sources
- Centers for Medicare & Medicaid Services, IRA implementation guidance, 2025–2026.
- CMS BALANCE model fact sheet and participating plan directory.
- Medicare Part D benefit parameters, 2026.
- Medicare Prescription Payment Plan guidance, CMS.
- Treat and Reduce Obesity Act legislative summary.
- MedSwitcher Medicare coverage database, updated April 2026.